🇺🇸 BMRN — BioMarin Pharmaceutical Inc.

Salud Compra
← Volver

Precio actual

55,66 USD

Máx. histórico

149,13

4124 días

Caída desde máximo

-62,68%

Rango 52 semanas

49,26 – 70,98

Variación hoy

-3,10%

Cierre anterior

57,44

Rango de hoy

52,00 – 56,32

Volumen hoy

4.698.487

Peor caída histórica

-90,58%

01/03/2000 → 27/08/2002

Recuperado en 1960 días

Volatilidad anualizada ⓘ

49,11%

Información
Nombre completo
BioMarin Pharmaceutical Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
3.221
PER ⓘ
150,43 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
91,33 USD (puede no estar actualizado)
Primera cotización
26/07/1999
Precio actualizado
hace 21 horas
Sobre la empresa

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
30/11/2001 12,11 12,49 11,96 12,00 -0,41% 4,38% 89.100
29/11/2001 12,24 12,38 11,92 12,05 +0,33% 3,76% 111.100
28/11/2001 12,36 12,60 12,00 12,01 -5,43% 4,85% 76.200
27/11/2001 12,39 12,89 12,30 12,70 -0,24% 4,76% 224.600
26/11/2001 12,32 12,75 12,25 12,73 +2,74% 4,06% 86.100
23/11/2001 12,40 12,65 12,23 12,39 -2,13% 3,39% 67.100
21/11/2001 12,29 12,70 12,15 12,66 +2,43% 4,48% 118.500
20/11/2001 12,15 12,65 12,15 12,36 -0,64% 4,12% 180.100
19/11/2001 12,20 12,45 11,90 12,44 +3,41% 4,51% 95.200
16/11/2001 11,90 12,15 11,79 12,03 -0,25% 3,03% 159.700
15/11/2001 12,04 12,15 12,00 12,06 +0,08% 1,25% 121.300
14/11/2001 11,75 12,10 11,67 12,05 +4,06% 3,66% 294.900
13/11/2001 11,56 11,91 11,50 11,58 -0,17% 3,55% 162.600
12/11/2001 11,75 11,80 10,99 11,60 -4,84% 6,89% 190.000
09/11/2001 11,84 12,35 11,75 12,19 +1,16% 5,07% 515.000
08/11/2001 12,32 12,38 11,85 12,05 -2,90% 4,30% 1.256.200
07/11/2001 12,61 12,75 12,35 12,41 -4,17% 3,17% 518.100
06/11/2001 12,25 13,05 12,19 12,95 -1,82% 7,02% 1.574.000
05/11/2001 12,45 13,24 12,20 13,19 +2,49% 8,35% 1.435.000
02/11/2001 13,19 13,85 12,70 12,87 +28,57% 8,72% 3.841.100
01/11/2001 11,61 11,75 9,90 10,01 -12,19% 15,93% 409.500
31/10/2001 11,75 11,75 11,28 11,40 -0,87% 4,00% 343.300
30/10/2001 11,46 11,92 11,41 11,50 -0,86% 4,45% 289.500
29/10/2001 11,74 11,80 11,50 11,60 -0,43% 2,56% 423.100
26/10/2001 11,14 11,90 11,06 11,65 +5,33% 7,54% 257.300
25/10/2001 10,35 11,06 10,12 11,06 +6,04% 9,08% 126.200
24/10/2001 10,15 10,86 10,10 10,43 +2,96% 7,49% 108.200
23/10/2001 10,20 10,30 10,04 10,13 -0,10% 2,55% 130.800
22/10/2001 10,50 10,50 9,81 10,14 -2,22% 6,57% 132.500
19/10/2001 10,60 10,97 10,20 10,37 -5,73% 7,26% 95.100